Merck & Co., Inc. (MRK)
Merck & Co., Inc. (MRK) is a healthcare company (drug manufacturers - general) based in the United States. The share price is $143.70, down 0.53% on the day, which values the company at $354.24B. Price as of 17 Nov 2026, 17:33 UTC, from Yahoo Finance.
Key facts
- Share price
- $143.70−0.53% today
- Market value
- $354.24B
- P/E ratio
- 145.1×last 12 months
- Forward P/E
- 16.0×
- Dividend yield
- 2.33%
- Funk Score
- 59/100
- Against its own history
- Well above its usual priceusual price $95.05
- 200-week average
- $110.0131% above
Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.
Merck & Co., Inc. in more detail
MRK trades at 145.1× its last twelve months' earnings, 16.0× next year's expected earnings, 5.3× sales. Measured against its own history, the price is 51% above what its usual multiples would imply ($95.05) — well above its usual price. It sits 31% above its 200-week average of $110.01.
Over the last five fiscal years Merck & Co., Inc. has compounded revenue 9.4% a year, earnings per share 21.2% a year, free cash flow 16.2% a year. Its Funk Score is 59 out of 100 (financial strength 6.5, profitability 9.0, growth 7.1, value 1.1, each out of 10).
In its favour: Altman Z in the safe zone; Five straight years of revenue growth. Worth checking: Debt is growing faster than cash flow.
23 of the superinvestors tracked here hold MRK, including Bill Smead (7.1% of the portfolio), Thomas Kahn (4.9% of the portfolio), Bill Nygren (2.1% of the portfolio).
Superinvestors holding MRK
23 of the investors tracked here report a position in their latest 13F filing.
- Bill Smead Smead Capital Management7.12% of portfolio · $335.1M · trimmed · Q3 2026
- Thomas Kahn Kahn Brothers4.93% of portfolio · $29.7M · trimmed · Q3 2026
- Bill Nygren Harris Associates (Oakmark)2.06% of portfolio · $1.6B · trimmed · Q2 2026
- Howard Gleicher Aristotle Capital Management2.03% of portfolio · $892.5M · trimmed · Q3 2026
- Ken Fisher Fisher Investments1.74% of portfolio · $6.1B · added · Q3 2026
- Jeremy Grantham (co-founder) GMO (Grantham, Mayo, Van Otterloo)1.57% of portfolio · $729.5M · trimmed · Q3 2026
- Charles Brandes (founder) Brandes Investment Partners1.49% of portfolio · $217.2M · trimmed · Q3 2026
- Josef Lakonishok LSV Asset Management1.36% of portfolio · $737.8M · trimmed · Q3 2026
- Prem Watsa Fairfax Financial0.95% of portfolio · $25.1M · Q3 2026
- Christopher Bloomstran Semper Augustus0.65% of portfolio · $5.7M · Q2 2026
- Sarah Ketterer Causeway Capital Management0.61% of portfolio · $54.2M · trimmed · Q3 2026
- Mark Boyar Boyar Asset Management0.51% of portfolio · $813.3K · trimmed · Q3 2026
- Cliff Asness AQR Capital Management0.36% of portfolio · $1B · trimmed · Q2 2026
- Temasek Temasek Holdings0.34% of portfolio · $124.2M · added · Q3 2026
- David Shaw (founder) D. E. Shaw & Co.0.22% of portfolio · $351.8M · trimmed · Q2 2026
- Brandon Haley Holocene Advisors0.19% of portfolio · $80.7M · added · Q2 2026
- Joel Greenblatt Gotham Asset Management0.16% of portfolio · $68M · added · Q2 2026
- Ken Griffin Citadel Advisors0.14% of portfolio · $248.5M · trimmed · Q2 2026
- Mairs & Power team Mairs & Power0.07% of portfolio · $7.4M · trimmed · Q3 2026
- Murray Stahl Horizon Kinetics0.05% of portfolio · $4M · trimmed · Q3 2026
- Dodge & Cox team Dodge & Cox0.01% of portfolio · $19.1M · trimmed · Q3 2026
- Rajiv Jain GQG Partners0.01% of portfolio · $3.3M · trimmed · Q3 2026
- Thomas Russo Gardner Russo & Quinn0.00% of portfolio · $238.8K · added · Q3 2026
Health Care companies of similar size
- Eli LillyLLY
- Johnson & JohnsonJNJ
- AbbVieABBV
- UnitedHealth GroupUNH
- NovartisNVS
- AstraZenecaAZN
- Thermo Fisher ScientificTMO
- AmgenAMGN
- Gilead SciencesGILD
- Abbott LaboratoriesABT
- Novo NordiskNVO
- PfizerPFE
Side by side:MRK vs UNH (Merck & Co., Inc. vs UnitedHealth Group)MRK vs NVS (Merck & Co., Inc. vs Novartis)MRK vs ABBV (Merck & Co., Inc. vs AbbVie)MRK vs AZN (Merck & Co., Inc. vs AstraZeneca)MRK vs JNJ (Merck & Co., Inc. vs Johnson & Johnson)
All health care companies by market valueLargest companies in the United StatesAll stocks A–Z
Merck & Co., Inc. (MRK): questions and answers
What is MRK's P/E ratio?
Merck & Co., Inc. trades at 145.1× its last twelve months' earnings and 16.0× next year's expected earnings. At its fiscal year-ends over the past 18 years the P/E ranged from 6.5× to 128.7×, with a median of 21.6×.
What is MRK's PEG ratio?
Merck & Co., Inc.'s PEG ratio is 3.58 — its P/E divided by its expected earnings growth. Around 1 is the classic sign of a price that matches the growth; well above it means the growth is being paid for in advance.
What is Merck & Co., Inc.'s market cap?
Merck & Co., Inc. is valued at $354.24B at a share price of $143.70.
Is MRK overvalued or undervalued?
Against its own history, MRK is well above its usual price: the price is 51% above the $95.05 implied by the median multiples it has traded at (price / earnings, price / sales, price / book, price / free cash flow). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.
Is MRK above its 200-week moving average?
Yes. MRK is 30.6% above its 200-week average of $110.01. Long-term investors watch that line because strong companies rarely trade below it for long.
How fast is Merck & Co., Inc. growing?
Over the last five fiscal years Merck & Co., Inc.'s revenue grew 9.4% a year and its earnings per share 21.2% a year; over ten years revenue grew 5.1% a year.
Learn to read these numbers
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
- Free cash flow and FCF yield explained
Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.
Cite this page
Funkfolio, “Merck & Co., Inc. (MRK) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/MRK
Underlying data: Yahoo Finance; company filings with the SEC.